This does not assist the "non-fatal decompensated heart failure events" but instead:
“The trial results show that rexlemestrocel-L significantly reduces cardiovascular mortality when used early in heart failure patients at risk of disease progression"
Holy crap we just hit the big time, so (REVASCOR®) doesn't assist people that are not going die, instead, it stops heart failure mortality by 60% in people who would otherwise die!!! This is HUGE news, what is the market for heart failure, it is the leading cause of death, which MSB can halt by 60%...
who knows what this share price will get to once the market digests this news but certainly hold on...
This does not assist the "non-fatal decompensated heart failure...
-
- There are more pages in this discussion • 941 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Add MSB (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
$1.13 |
Change
0.035(3.21%) |
Mkt cap ! $1.284B | |||
| Open | High | Low | Value | Volume |
| $1.09 | $1.13 | $1.07 | $3.910M | 3.535M |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 2 | 27197 | $1.11 |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| $1.13 | 43578 | 3 |
View Market Depth
| Last trade - 16.10pm 27/09/2024 (20 minute delay) ? |
| MSB (ASX) Chart |